Jaguar Health, Inc.
Jaguar Health, Inc. (JAGX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
jagx · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.98
Consensus
$12.98
+375.5% upside
Low
$12.98
Median: $12.98 · Last Close: $2.73
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.59 | ↓ 5.00% |
1-day model range: $2.5–$2.68. Peak: $2.68 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · JAGX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-07-07 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2020-11-25 | Aegis Capital | Maintains | Buy→Buy |
| 2020-11-25 | H.C. Wainwright | Maintains | Buy→Buy |
| 2020-11-25 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2020-11-25 | Rodman & Renshaw | Maintains | Buy→Buy |
| 2019-11-18 | H.C. Wainwright | Maintains | Buy→Buy |
| 2019-09-12 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2017-07-11 | Rodman & Renshaw | Maintains | Buy→Buy |
| 2015-11-12 | Aegis Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Jaguar Health, Inc. (JAGX) stock. Of the recent 9 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover JAGX.
Analyst Recommendation Trends
JAGX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$10M
↓ 18.9% YoY
Revenue Next Year
$11M
↑ 10.9% YoY
EPS This Year
$-40.68
EPS Next Year
$-700.00
↑ 1620.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast JAGX EPS of $-40.68 for the current fiscal year, based on estimates from 1 analysts. The JAGX revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The JAGX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus JAGX price target is $12.98 (+375.5% upside), with an analyst consensus of Buy.
The JAGX short-term stock prediction for tomorrow is $2.59 (-5.00%).
Jaguar Health, Inc. trades on NASDAQ under the ticker JAGX. The JAGX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
JAGX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month JAGX price target is $12.98, with a high forecast of $12.98 and a low of $12.98. The median price target is shown in the chart above when available. This implies +375.5% potential upside from the current price of $2.73.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.